Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat

Diabetic Medicine

Volumn 25, Issue 7, 2008, Pages 818-825

  Hotta, N ^a   Kawamori, R ^b   Atsumi, Y ^c   Baba, M ^d   Kishikawa, H ^e   Nakamura, J ^f   Oikawa, S ^g   Yamada, N ^h   Yasuda, H ⁱ   Shigeta, Y ⁱ  

^a CHUBU ROSAI HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c SAISEIKAI CENTRAL HOSPITAL   (Japan)

^d HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

^f NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NIPPON MEDICAL SCHOOL   (Japan)

^h UNIVERSITY OF TSUKUBA   (Japan)

ⁱ SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Aldose reductase inhibitor; Diabetic peripheral neuropathy; Good condition of blood glucose level; Polyol pathway

Indexed keywords

ANTIHYPERTENSIVE AGENT; EPALRESTAT; HEMOGLOBIN A1C; INSULIN; DRUG DERIVATIVE; ENZYME INHIBITOR; GLYCOSYLATED HEMOGLOBIN; RHODANINE; THIAZOLIDINE DERIVATIVE;

ADULT; ARTICLE; BRAIN INFARCTION; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; ECZEMA; FEMALE; GLYCEMIC CONTROL; HOT FLUSH; HUMAN; LIMB WEAKNESS; LIVER FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOTOR NERVE CONDUCTION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RETINOPATHY; RIGIDITY; SIDE EFFECT; THIRST; VERTIGO; AGED; DIABETIC RETINOPATHY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; ENZYME INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; PATIENT SELECTION; PROTEINURIA; RHODANINE; THIAZOLIDINES; TREATMENT OUTCOME;

EID: 49649122550     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02490.x     Document Type: Article

References (27)

1. Ziegler D. Treatment of neuropathic pain. In: Gries FA, Cameron NE, Low PA, Ziegler D, eds. Textbook of Diabetic Neuropathy. Stuttgart: Georg Thieme Verlag, 2003; 211-224.
2. Hotta N. New concepts and insights on pathogenesis and treatment of diabetic complications: polyol pathway and its inhibition. Nagoya J Med Sci 1997; 60: 89-100.
3. Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002; 50: 325-392.
4. Feldman EL, Sullivan KA, Stevens MJ. Polyolpathway: aldose reductase inhibitors-hope for the future? In: Gries FA, Cameron NE, Low PA, Ziegler D, eds. Textbook of Diabetic Neuropathy. Stuttgart: Georg Thieme Verlag, 2003; 112-115.
5. Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001; 24: 1776-1782.
6. Hotta N, Yasuda K, Sumita Y, Sano T, Kakuta H, Nagashima M et al. Effects of a novel aldose reductase inhibitor, fidarestat (SNK-860), on vibration perception threshold and subjective symptoms in patients with diabetic polyneuropathy: An open-label pilot study. Clin Drug Invest 2004; 24: 671-680.
7. Bril V, Buchanan RA, the AS-3201 Study Group. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2004; 27: 2369-2375.
8. Bril V, Buchanan RA, the Ranirestat Study Group. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006; 29: 68-72.
9. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999; 53: 580-591.
10. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006; 29: 1538-1544.
11. Santiago JV, Snksen PH, Boulton AJ, Macleod A, Beg M, Bochenek W et al. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. J Diabetes Complications 1993; 7: 170-178.
12. Nakayama M, Nakamura J, Hamada Y, Chaya S, Mizubayashi R, Yasuda Y et al. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic europathy. Diabetes Care 2001; 24: 1093-1098.
13. Maser RE, Laudadio C, DeCherney GS. The effects of age and diabetes mellitus on nerve function. J Am Geriatr Soc 1993; 41: 1202-1204.
14. Boulton AJ, Levin S, Comstock J. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic europathy. Diabetologia 1990; 33: 431-437.
15. illings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Info J 1991; 25: 411-24.
16. Department of Health and Human Services Food and Drug Administration. International conference on harmonisation; guidance on statistical principles for clinical trials; availability-FDA. Notice. Fed Regist 1998; 63: 49583-49598.
17. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29: 1518-1522.
18. Boulton AJM. Treatments for diabetic neuropathy. Curr Diab Rep 2001; 1: 127-132.
19. Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004; 88: 947-999.
20. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-350.
21. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W et al. Effect of angiotensin-converting enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352: 1978-1981.
22. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
23. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002; 25: 2048-2052.
24. Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988; 1: 9-11.
25. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652.
26. Thamer M, Ray NF, Taylor T. Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas. Clin Ther 1999; 21: 1387-1400.
27. Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M et al. Efficacy of glimepiride in Japanese Type 2 diabetic subjects. Diabetes Res Clin Pract 2005; 68: 250-257.